Oncothyreon (ONTY) Posts Wider than Expected Q4 Loss of 27c; Guides FY12 Expenses
Tweet
Share
E-mailGet Alerts ONTY Hot Sheet
Join SI Premium – FREE
Oncothyreon, Inc. (NASDAQ: ONTY) reported Q4 EPS of ($0.27), $0.12 worse than the analyst estimate of ($0.15).
Expenses in 2012 are expected to be higher when compared to 2011, primarily as a result of the more advanced clinical development of PX-866 and the Phase 1 clinical trial of ONT-10. Oncothyreon currently expects cash used in operations in 2012 to be between approximately $30.0 and approximately $33.0 million. As a result, Oncothyreon estimates that its existing cash, cash-equivalents and investments will be sufficient to fund operations for at least the next 12 months.
For earnings history and earnings-related data on Oncothyreon, Inc. (ONTY) click here.
Expenses in 2012 are expected to be higher when compared to 2011, primarily as a result of the more advanced clinical development of PX-866 and the Phase 1 clinical trial of ONT-10. Oncothyreon currently expects cash used in operations in 2012 to be between approximately $30.0 and approximately $33.0 million. As a result, Oncothyreon estimates that its existing cash, cash-equivalents and investments will be sufficient to fund operations for at least the next 12 months.
For earnings history and earnings-related data on Oncothyreon, Inc. (ONTY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PepsiCo (PEP) tops earnings, revenue expectations in Q1
- LKQ Corporation (LKQ) Misses Q1 EPS by 13c, provides guidance
- Novartis hikes full-year guidance as Q1 results exceed estimates, shares pop
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
